AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11036957 — intervention group
Group type: COMPARATOR
Intervention: Control group (systemic chemotherapy only)
Number of subjects: 260
Study 11036957 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraportal chemotherapy
Number of subjects: 260
Study 8869649 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled anesthetics
Number of subjects: 1227
Study 8869649 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous anesthesia
Number of subjects: 1227
Study 8869649 — intervention group
Group type: EXPERIMENTAL
Intervention: Local-regional anesthetic procedures (axilar blocks and local infiltrations)
Number of subjects: 1227
Study 8869649 — intervention group
Group type: EXPERIMENTAL
Intervention: High abdominal surgery
Number of subjects: 1227
Study 8869649 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower abdominal surgery
Number of subjects: 1227
Study 8869649 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineal surgery
Number of subjects: 1227
Study 8869649 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA III classification, procedures lasting longer than 120 minutes, upper abdominal surgery, isoflurane and pancuronium use, adverse events
Number of subjects: 1227
Study 1325176 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose natural interferon alfa (nIFN‐alpha)
Number of subjects: 237
Study 1325176 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy (CAP)
Number of subjects: 237
Study 1325176 — intervention group
Group type: COMPARATOR
Intervention: Control (no maintenance treatment)
Number of subjects: 237
Study 6151145 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceruletide (40 micrograms, intramuscularly, twice for 2 consecutive weeks)
Number of subjects: 6
Study 29792582 — intervention group
Group type: EXPERIMENTAL
Intervention: Enough! training (1-hour online course)
Number of subjects: 134
Study 29792582 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B, posttest only)
Number of subjects: 134
Study 29792582 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C, pre- and posttests)
Number of subjects: 134
Study 28914750 — intervention group
Group type: EXPERIMENTAL
Intervention: Live-attenuated influenza vaccine (LAIV)
Number of subjects: 1151
Study 28914750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1151
Study 27095323 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-benefit intervention with Professional e-coach (CB Pro)
Number of subjects: 75
Study 27095323 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-benefit intervention with Peer e-coach (CB Peer)
Number of subjects: 75
Study 27095323 — intervention group
Group type: COMPARATOR
Intervention: Standard arm (traditional weight maintenance strategies)
Number of subjects: 75
Study 25363100 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive supervision in intervention districts
Number of subjects: 340
Study 25363100 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supportive supervision)
Number of subjects: 340
Study 21786162 — intervention group
Group type: EXPERIMENTAL
Intervention: Hay + 150 g moringa leaf (T2)
Number of subjects: 24
Study 21786162 — intervention group
Group type: EXPERIMENTAL
Intervention: Hay + 300 g moringa leaf (T3)
Number of subjects: 24
Study 21786162 — intervention group
Group type: EXPERIMENTAL
Intervention: Hay + 450 g moringa leaf (T4)
Number of subjects: 24
Study 21786162 — intervention group
Group type: COMPARATOR
Intervention: Rhodes grass hay (T1)
Number of subjects: 24
Study 20522670 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxy polyethylene glycol‐epoetin beta
Number of subjects: 490
Study 20522670 — intervention group
Group type: COMPARATOR
Intervention: Darbepoetin alfa
Number of subjects: 490
Study 20522670 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 490
Study 18616066 — intervention group
Group type: EXPERIMENTAL
Intervention: Healing Touch (HT)
Number of subjects: 237
Study 18616066 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 237
Study 18616066 — intervention group
Group type: COMPARATOR
Intervention: Visitor (partial intervention)
Number of subjects: 237
Study 16097539 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressurization of cement
Number of subjects: 50
Study 16097539 — intervention group
Group type: COMPARATOR
Intervention: Fingerpacking of cement
Number of subjects: 50
Study 16097539 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall group
Number of subjects: 50
Study 12583554 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin‐clavulanic acid (2.2 g)
Number of subjects: 511
Study 12583554 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin (2 g)
Number of subjects: 511
Study 12583554 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin‐clavulanic acid (2.2 g) and Cefazolin (2 g)
Number of subjects: 511
Study 10626237 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofazimine 50 mg daily for six months in addition to the WHO regimen
Number of subjects: 300
Study 10626237 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving standard WHO regimen (six doses of once a month rifampicin with daily dapsone for six months)
Number of subjects: 300
Study 10626237 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofazimine containing regimen
Number of subjects: 300
Study 10626237 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 300
Study 7582283 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with high serum IgE levels (highest tertile)
Number of subjects: 1177
Study 7582283 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthmatic parents with moderate serum IgE levels
Number of subjects: 1177
Study 7582283 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthmatic children
Number of subjects: 1177
Study 7582283 — intervention group
Group type: COMPARATOR
Intervention: General population
Number of subjects: 1177
Study 8151095 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin plus Nicardipine
Number of subjects: 18
Study 8151095 — intervention group
Group type: COMPARATOR
Intervention: Vasopressin alone
Number of subjects: 18
Study 3636818 — intervention group
Group type: EXPERIMENTAL
Intervention: Z‐track intramuscular injection technique
Number of subjects: 50
Study 3636818 — intervention group
Group type: COMPARATOR
Intervention: Standard injection technique
Number of subjects: 50
Study 29625016 — intervention group
Group type: EXPERIMENTAL
Intervention: Reliving or having an inspirational experience
Number of subjects: 0
Study 29625016 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting inspirational experiences
Number of subjects: 0
Study 29625016 — intervention group
Group type: EXPERIMENTAL
Intervention: Being inspired by someone or something
Number of subjects: 0
Study 27086768 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E‐fortified whey beverage (15g of whey protein concentrate + 600IU of vitamin E)
Number of subjects: 92
Study 27086768 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey beverage (15g of whey protein concentrate)
Number of subjects: 92
Study 27086768 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (600IU)
Number of subjects: 92
Study 27086768 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 92
Study 27101668 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal endoscope negative pressure cleaning and sinupret drops
Number of subjects: 153
Study 27101668 — intervention group
Group type: COMPARATOR
Intervention: Nasal endoscope negative pressure cleaning and normal saline spray washing
Number of subjects: 153
Study 27101668 — intervention group
Group type: COMPARATOR
Intervention: Saline nasal irrigation through nasal catheter
Number of subjects: 153
Study 23282127 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (5 mg per day)
Number of subjects: 50
Study 23282127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 22043464 — intervention group
Group type: EXPERIMENTAL
Intervention: Short implants (5 to 8.5 mm)
Number of subjects: 28
Study 22043464 — intervention group
Group type: COMPARATOR
Intervention: Bone augmentation with autogenous bone for longer implants (>11.5 mm)
Number of subjects: 28
Study 22043464 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (short implants and augmented longer implants)
Number of subjects: 28
Study 19916291 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture plus moxibustion (EA-Moxi)
Number of subjects: 60
Study 19916291 — intervention group
Group type: COMPARATOR
Intervention: Medication with Omeperazole (20 mg, qd.)
Number of subjects: 60
Study 19916291 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life measures (SF-36 questionnaire) in EA-Moxi group
Number of subjects: 60
Study 19916291 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life measures (SF-36 questionnaire) in both groups
Number of subjects: 60
Study 16954725 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle modification program
Number of subjects: 34
Study 16954725 — intervention group
Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 34
Study 15026292 — intervention group
Group type: EXPERIMENTAL
Intervention: Moms on the Move (PA intervention)
Number of subjects: 44
Study 15026292 — intervention group
Group type: COMPARATOR
Intervention: Counseling on self‐breast examination (control)
Number of subjects: 44
Study 11297595 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone 300 mg/day (TGZ-300)
Number of subjects: 410
Study 11297595 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone 600 mg/day (TGZ-600)
Number of subjects: 410
Study 11297595 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (all doses)
Number of subjects: 410
Study 11297595 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 410
Study 9508155 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with chlorthalidone (12.5-25 mg/d)
Number of subjects: 104
Study 9508155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 8070930 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin/sulbactam (33.3/16.7 mg/kg bodyweight)
Number of subjects: 21
Study 3144172 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based TPN (70% CHO, 30% lipid)
Number of subjects: 0
Study 3144172 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate-based TPN (100% CHO)
Number of subjects: 0
Study 29989014 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate
Number of subjects: 120
Study 29989014 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium acetate
Number of subjects: 120
Study 29989014 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 120
Study 27580827 — intervention group
Group type: EXPERIMENTAL
Intervention: Social facilitation maintenance treatment (4 months, 16 outpatient group sessions)
Number of subjects: 72
Study 27580827 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control condition)
Number of subjects: 72
Study 27580827 — intervention group
Group type: EXPERIMENTAL
Intervention: Social facilitation maintenance treatment
Number of subjects: 72
Study 24732860 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening exercises
Number of subjects: 600
Study 24732860 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexibility exercises
Number of subjects: 600
Study 24732860 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening exercises with abdominal bracing
Number of subjects: 600
Study 24732860 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexibility exercises with abdominal bracing
Number of subjects: 600
Study 24732860 — intervention group
Group type: COMPARATOR
Intervention: Non-bracing groups (Strengthening and Flexibility)
Number of subjects: 600
Study 21736587 — intervention group
Group type: EXPERIMENTAL
Intervention: Robenacoxib 5 mg/kg once daily for 28 days
Number of subjects: 0
Study 21736587 — intervention group
Group type: EXPERIMENTAL
Intervention: Robenacoxib 10 mg/kg once daily for 28 days
Number of subjects: 0
Study 21736587 — intervention group
Group type: EXPERIMENTAL
Intervention: Robenacoxib 2 mg/kg twice daily for 42 days
Number of subjects: 0
Study 21736587 — intervention group
Group type: EXPERIMENTAL
Intervention: Robenacoxib 6 mg/kg twice daily for 42 days
Number of subjects: 0
Study 21736587 — intervention group
Group type: EXPERIMENTAL
Intervention: Robenacoxib 10 mg/kg twice daily for 42 days
Number of subjects: 0
Study 21736587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21077526 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (1 pg kg(‐1) IV bolus)
Number of subjects: 72
Study 21077526 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (0.5 microg kg(‐1) IV bolus)
Number of subjects: 72
Study 18498919 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (0.4 mg/kg/d in children <or=62.5 kg or 25 mg/d in children >62.5 kg)
Number of subjects: 21
Study 18498919 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 21
Study 15880468 — intervention group
Group type: EXPERIMENTAL
Intervention: DM1 patients (MVICs)
Number of subjects: 25
Study 15880468 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (MVICs)
Number of subjects: 25
Study 12825804 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Dalteparin 2 x 5,000U)
Number of subjects: 172
Study 12825804 — intervention group
Group type: COMPARATOR
Intervention: Standard heparin (UFH) (5,000U bolus followed by infusion to raise APTT to 1.5 times control)
Number of subjects: 172
Study 12825804 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LMWH and UFH
Number of subjects: 172
Study 10213233 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle tap
Number of subjects: 201
Study 10213233 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanized biopsy
Number of subjects: 201
Study 10213233 — intervention group
Group type: EXPERIMENTAL
Intervention: Abort eyes (initial needle tap aborted to mechanized biopsy)
Number of subjects: 201
Study 2714504 — intervention group
Group type: EXPERIMENTAL
Intervention: Squatting position during delivery
Number of subjects: 0
Study 2714504 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 929109 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzilonium bromide (Ulcoban Prolongatum, Parke, Davis & Co.)
Number of subjects: 50
Study 929109 — intervention group
Group type: COMPARATOR
Intervention: Selective proximal vagotomy (SPV)
Number of subjects: 50
Study 31849362 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary pain rehabilitation program
Number of subjects: 0
Study 31849362 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic evaluation from a societal perspective
Number of subjects: 0
Study 30971276 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated gum (200 mg caffeine)
Number of subjects: 17
Study 30971276 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 17
Study 28209122 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centred and health-promoting intervention
Number of subjects: 270
Study 28209122 — intervention group
Group type: COMPARATOR
Intervention: Matched control group
Number of subjects: 270
Study 26385956 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intrahospital RIC + PostC in addition to primary PCI
Number of subjects: 696
Study 26385956 — intervention group
Group type: EXPERIMENTAL
Intervention: PostC in addition to PCI
Number of subjects: 696
Study 26385956 — intervention group
Group type: COMPARATOR
Intervention: Conventional PCI (control)
Number of subjects: 696
Study 23349309 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic transplantation in first remission (15 sibling donors and 16 unrelated donors)
Number of subjects: 85
Study 23349309 — intervention group
Group type: COMPARATOR
Intervention: Post-remission chemotherapy
Number of subjects: 85
Study 23349309 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger patients (<25 years)
Number of subjects: 85
Study 21315644 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemoradiation (60 Gy, 2 Gy/fraction; concomitant 5‐fluoro‐uracil infusion, 300 mg/m(2) per day, days 1‐5 for 6 weeks; cisplatin, 20 mg/m(2) per day, days 1‐5 during weeks 1 and 5) followed by maintenance gemcitabine (1000 mg/m(2) weekly, 3/4 weeks)
Number of subjects: 119
Study 21315644 — intervention group
Group type: COMPARATOR
Intervention: Induction gemcitabine (1000 mg/m(2) weekly for 7 weeks) followed by maintenance gemcitabine (1000 mg/m(2) weekly, 3/4 weeks)
Number of subjects: 119
Study 19827653 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrostimulation of the skeletal muscles (EMS) in addition to standard rehabilitation (n = 54)
Number of subjects: 101
Study 19827653 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (Control group, n = 47)
Number of subjects: 101
Study 18261273 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole oral solution (20 ml once a day for 15 days)
Number of subjects: 60
Study 18261273 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole (150 mg once a day for 15 days)
Number of subjects: 60
Study 15238591 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (1 mg/kg every 12 hours)
Number of subjects: 3987
Study 15238591 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (weight-adjusted intravenous)
Number of subjects: 3987
Study 15238591 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 3987
Study 15238591 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 3987
Study 11600518 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human GH (2.0 IU/d)
Number of subjects: 22
Study 11600518 — intervention group
Group type: COMPARATOR
Intervention: no treatment (control)
Number of subjects: 22
Study 9674293 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin 0.25 mg/day
Number of subjects: 21
Study 9674293 — intervention group
Group type: COMPARATOR
Intervention: Enalapril up to 20 mg/day
Number of subjects: 21
Study 7979931 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic strength tests for plantar flexion
Number of subjects: 0
Study 7979931 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic strength tests for dorsiflexion
Number of subjects: 0
Study 7979931 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic strength tests for plantar flexion and dorsiflexion
Number of subjects: 0
Study 7979931 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced examiners (physical therapists)
Number of subjects: 0
Study 7979931 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic strength tests
Number of subjects: 0
Study 3393620 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo and exposure therapy
Number of subjects: 23
Study 3393620 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine and exposure therapy
Number of subjects: 23
Study 3393620 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine and initial antiexposure instructions
Number of subjects: 23
Study 3393620 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonanxious controls)
Number of subjects: 23
Study 421317 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week intervention including total abstinence from caffeine and smoking, reduction of alcohol intake, and a physical conditioning program
Number of subjects: 81
Study 421317 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 81
Study 30898938 — intervention group
Group type: EXPERIMENTAL
Intervention: SLN biopsy only
Number of subjects: 950
Study 30898938 — intervention group
Group type: COMPARATOR
Intervention: SLN biopsy + pelvic lymphadenectomy
Number of subjects: 950
Study 27614675 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acid-based parenteral nutrition (Omegaven, Fresenius-Kabi, Germany) for 5 days postoperatively
Number of subjects: 312
Study 27614675 — intervention group
Group type: COMPARATOR
Intervention: Structolipid alone (control group) for 5 days postoperatively
Number of subjects: 312
Study 25878306 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly cross‐linked polyethylene liners
Number of subjects: 46
Study 25878306 — intervention group
Group type: COMPARATOR
Intervention: Ultra‐high molecular weight polyethylene liners
Number of subjects: 46
Study 25878306 — intervention group
Group type: EXPERIMENTAL
Intervention: Tantalum cups
Number of subjects: 46
Study 25878306 — intervention group
Group type: COMPARATOR
Intervention: Titanium cups
Number of subjects: 46
Study 25878306 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 46
Study 23168119 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic dilation
Number of subjects: 0
Study 23168119 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin injection
Number of subjects: 0
Study 23168119 — intervention group
Group type: COMPARATOR
Intervention: Surgical myotomy
Number of subjects: 0
Study 23168119 — intervention group
Group type: EXPERIMENTAL
Intervention: Per oral endoscopic myotomy
Number of subjects: 0
Study 22237467 — intervention group
Group type: EXPERIMENTAL
Intervention: O-3FA enteral immunoenhancing diet (IED)
Number of subjects: 221
Study 22237467 — intervention group
Group type: COMPARATOR
Intervention: Standard enteral nutrition (SEN)
Number of subjects: 221
Study 22237467 — intervention group
Group type: COMPARATOR
Intervention: Control group (postoperative supplementation alone)
Number of subjects: 221
Study 20655182 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine plus naltrexone
Number of subjects: 31
Study 20655182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 17293025 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodynamics at baseline
Number of subjects: 114
Study 17293025 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodynamics at 6 months
Number of subjects: 114
Study 17293025 — intervention group
Group type: EXPERIMENTAL
Intervention: BOOI > 65
Number of subjects: 114
Study 17293025 — intervention group
Group type: EXPERIMENTAL
Intervention: BOOI >= 50
Number of subjects: 114
Study 15300317 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized interviews (SCID-I, DSM-IV)
Number of subjects: 117
Study 15300317 — intervention group
Group type: COMPARATOR
Intervention: Routine diagnoses (discharge letters)
Number of subjects: 117